Your browser is no longer supported. Please, upgrade your browser.
COCP [NASD]
Cocrystal Pharma, Inc.
Index- P/E- EPS (ttm)-0.18 Insider Own27.86% Shs Outstand69.39M Perf Week-22.86%
Market Cap81.90M Forward P/E- EPS next Y-0.20 Insider Trans-2.65% Shs Float22.65M Perf Month-16.28%
Income-9.60M PEG- EPS next Q-0.04 Inst Own14.20% Short Float8.17% Perf Quarter-46.53%
Sales2.00M P/S40.95 EPS this Y88.40% Inst Trans-0.17% Short Ratio0.12 Perf Half Y30.85%
Book/sh0.76 P/B1.42 EPS next Y-5.60% ROA-20.20% Target Price- Perf Year13.68%
Cash/sh0.44 P/C2.48 EPS next 5Y- ROE-21.40% 52W Range0.76 - 3.46 Perf YTD-20.59%
Dividend- P/FCF- EPS past 5Y40.70% ROI-18.30% 52W High-68.79% Beta0.73
Dividend %- Quick Ratio25.00 Sales past 5Y91.60% Gross Margin- 52W Low42.11% ATR0.23
Employees13 Current Ratio25.00 Sales Q/Q25.00% Oper. Margin- RSI (14)42.34 Volatility9.95% 14.79%
OptionableNo Debt/Eq0.00 EPS Q/Q98.50% Profit Margin- Rel Volume0.66 Prev Close1.11
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume15.35M Price1.08
Recom2.00 SMA20-15.58% SMA50-22.02% SMA200-22.89% Volume10,153,984 Change-2.70%
Jul-08-20Initiated H.C. Wainwright Buy $5
May-07-21 04:05PM  
May-05-21 09:25AM  
06:37AM  
May-04-21 06:41PM  
02:40PM  
09:05AM  
May-03-21 01:14PM  
08:00AM  
Mar-26-21 02:51AM  
Mar-17-21 08:30AM  
Mar-10-21 08:00AM  
Mar-09-21 07:00AM  
Mar-02-21 11:28AM  
08:00AM  
Jan-24-21 02:47AM  
Jan-21-21 08:36AM  
08:00AM  
Jan-20-21 12:18PM  
Jan-19-21 08:00AM  
Jan-14-21 08:00AM  
Jan-12-21 08:00AM  
Jan-05-21 08:00AM  
Dec-22-20 08:30AM  
Nov-29-20 07:40PM  
Nov-25-20 12:04AM  
Nov-24-20 09:46AM  
Nov-16-20 08:05AM  
Nov-10-20 08:05AM  
Nov-06-20 08:00AM  
Oct-19-20 08:05AM  
Oct-02-20 08:05AM  
Sep-08-20 08:00AM  
Sep-07-20 08:00AM  
Aug-31-20 12:05PM  
Aug-26-20 10:00PM  
05:35PM  
Aug-18-20 07:19AM  
Aug-06-20 08:05AM  
Aug-04-20 08:05AM  
May-28-20 03:25PM  
May-15-20 06:36AM  
May-14-20 07:05AM  
May-11-20 08:05AM  
Apr-22-20 08:05AM  
Apr-20-20 08:05AM  
Apr-15-20 08:05AM  
Mar-30-20 06:05AM  
Mar-11-20 09:40AM  
Mar-10-20 10:00AM  
Mar-09-20 03:00PM  
Mar-06-20 04:01PM  
Feb-28-20 02:00PM  
Feb-27-20 07:00AM  
Feb-25-20 03:25PM  
Feb-24-20 08:00AM  
Feb-17-20 02:35PM  
Feb-13-20 08:30AM  
Feb-11-20 08:35AM  
Feb-03-20 08:05AM  
Jan-29-20 09:45AM  
Dec-18-19 05:49PM  
Dec-04-19 08:00AM  
Nov-12-19 08:35AM  
Nov-11-19 08:35AM  
Oct-31-19 09:00AM  
Oct-30-19 04:45PM  
08:05AM  
Oct-16-19 09:22AM  
Oct-08-19 09:15AM  
Oct-01-19 08:00AM  
Sep-26-19 08:05AM  
Sep-10-19 01:11PM  
Sep-03-19 08:05AM  
Aug-21-19 08:05AM  
Aug-09-19 08:05AM  
Jul-26-19 08:10AM  
Jun-19-19 06:03AM  
May-20-19 08:05AM  
May-10-19 08:35AM  
Apr-01-19 08:35AM  
Mar-11-19 08:30AM  
Jan-22-19 04:00PM  
08:00AM  
Jan-18-19 04:18PM  
Jan-07-19 08:30AM  
Jan-03-19 10:35AM  
08:48AM  
08:30AM  
Nov-30-18 08:00AM  
Nov-29-18 11:05AM  
Nov-19-18 11:40AM  
09:25AM  
08:40AM  
Nov-18-18 09:00AM  
Nov-16-18 07:30PM  
10:37AM  
09:00AM  
Nov-15-18 04:28PM  
01:37PM  
09:51AM  
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schinazi Raymond F10% OwnerMay 04Sale2.95575,0001,696,2507,674,960May 06 06:00 PM